TBET Stock Overview
Tibet Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Tibetan medicines.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Tibet Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.000001 |
| 52 Week High | US$0.000001 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -100.00% |
| 5 Year Change | 0% |
| Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| TBET | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | -3.1% | -1.7% |
| 1Y | n/a | 11.5% | 22.4% |
Return vs Industry: Insufficient data to determine how TBET performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how TBET performed against the US Market.
Price Volatility
| TBET volatility | |
|---|---|
| TBET Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: TBET has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine TBET's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | n/a | Hong Yu | n/a |
Tibet Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Tibetan medicines. The company, through its operational entity, Yunnan Shangri-La Tibetan Pharmaceutical Group Limited (YSTP), develops products in China for promoting health in human respiratory, digestive, urinary, and reproductive systems. Its commercialized products include 25 Ingredients Mandrake Pill, which is used to regulate menses to treat endometritis, pelvic inflammations, and women’s anemia; 15 Ingredients Gentiana Pill to treat bronchitis, emphysema, asthma, and hoarseness; 28 Ingredients Pinang Pill for treating cold waist hip pain, pus hematuria, and testis swelling; 18 Ingredients Chebulic (Myrobalan) Frusemide Pill for the treatment of kidney problems, lumbar and kidney pain, frequent urination, turbid urine, diabetes, and spermatorrhea; and Pomegranate Nichirin Pill to treat indigestion, back and leg pain, frequent urination, foot edema, impotence, and nocturnal emission.
Tibet Pharmaceuticals, Inc. Fundamentals Summary
| TBET fundamental statistics | |
|---|---|
| Market cap | US$14.00 |
| Earnings (TTM) | US$10.82m |
| Revenue (TTM) | US$34.05m |
0.0x
P/E Ratio0.0x
P/S RatioIs TBET overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TBET income statement (TTM) | |
|---|---|
| Revenue | US$34.05m |
| Cost of Revenue | US$19.89m |
| Gross Profit | US$14.17m |
| Other Expenses | US$3.34m |
| Earnings | US$10.82m |
Last Reported Earnings
Sep 30, 2011
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did TBET perform over the long term?
See historical performance and comparison